Title:
PHARMACEUTICAL USE OF CORD BLOOD IMMUNOSUPPRESSIVE CELL
Document Type and Number:
WIPO Patent Application WO/2022/265124
Kind Code:
A1
Abstract:
The present invention relates to the pharmaceutical use of a cord blood immunosuppressive cell and, more specifically, the present invention provides the use of a human-derived cord blood immunosuppressive cell, which is selected in accordance with analysis of function and phenotype and a classification standard, as a new cell therapy product for anti-inflammation, anti-fibrosis, and prevention or treatment of myocardial infarction.
More Like This:
Inventors:
SOHN HYUN JUNG (KR)
KIM TAI GYU (KR)
KIM SU EON (KR)
JUNG SOO HYUN (KR)
CHO HYUN IL (KR)
LIM BANG GEUL (KR)
KIM EUN AH (KR)
KIM TAI GYU (KR)
KIM SU EON (KR)
JUNG SOO HYUN (KR)
CHO HYUN IL (KR)
LIM BANG GEUL (KR)
KIM EUN AH (KR)
Application Number:
PCT/KR2021/007420
Publication Date:
December 22, 2022
Filing Date:
June 14, 2021
Export Citation:
Assignee:
VIGENCELL INC (KR)
CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION (KR)
CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION (KR)
International Classes:
A61K35/51; A61P9/10; A61P29/00; A61P43/00; C12N5/0775; G01N33/50
Foreign References:
| KR20170010731A | 2017-02-01 | |||
| KR20080109705A | 2008-12-17 |
Other References:
KO JENNIFER S., RAYMAN PATRICIA, IRELAND JOANNA, SWAIDANI SHADI, LI GEQIANG, BUNTING KEVIN D., RINI BRIAN, FINKE JAMES H., COHEN P: "Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 70, no. 9, 1 May 2010 (2010-05-01), US, pages 3526 - 3536, XP093015776, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-09-3278
ANONYMOUS: "Boryung Pharmaceutical-Vigencell, "joint development" of immune cell therapy", BORYUNG PHARMACEUTICAL CO., LTD.-VIGENCELL INC., 8 September 2020 (2020-09-08), XP093015778, Retrieved from the Internet [retrieved on 20230119]
DIMITRY I GABRILOVICH , SRINIVAS NAGARAJ: "Myeloid-derived suppressor cells as regulators of the immune system", NATURE REVIEWS IMMUNOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 9, no. 3, 6 February 2009 (2009-02-06), London, pages 162 - 174, XP002588070, ISSN: 1474-1733, DOI: 10.1038/nri2506
ILBO JOONGANG: "[Healthy Family] Hope for Development of a New Drug to Catch 'GvHD', Another Enemy of Leukemia and Blood Cancer Patients", 21 December 2020 (2020-12-21), XP093015782, Retrieved from the Internet [retrieved on 20230119]
ANONYMOUS: "Boryung Pharmaceutical-Vigencell, "joint development" of immune cell therapy", BORYUNG PHARMACEUTICAL CO., LTD.-VIGENCELL INC., 8 September 2020 (2020-09-08), XP093015778, Retrieved from the Internet
DIMITRY I GABRILOVICH , SRINIVAS NAGARAJ: "Myeloid-derived suppressor cells as regulators of the immune system", NATURE REVIEWS IMMUNOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 9, no. 3, 6 February 2009 (2009-02-06), London, pages 162 - 174, XP002588070, ISSN: 1474-1733, DOI: 10.1038/nri2506
ILBO JOONGANG: "[Healthy Family] Hope for Development of a New Drug to Catch 'GvHD', Another Enemy of Leukemia and Blood Cancer Patients", 21 December 2020 (2020-12-21), XP093015782, Retrieved from the Internet
Attorney, Agent or Firm:
DANA PATENT LAW FIRM (KR)
Download PDF:
Previous Patent: METHOD AND APPARATUS FOR CARRYING OUT ULTRA-WIDEBAND COMMUNICATION
Next Patent: WASTE-SYNTHETIC-RESIN EMULSIFYING APPARATUS
Next Patent: WASTE-SYNTHETIC-RESIN EMULSIFYING APPARATUS